Hannah Brendan

Average Profitability
<0.0001%
Insider Buys Quantity
4
Insider Buys Sum
$111,715.69
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of Hannah Brendan

According to the SEC Form 4 filings, Hannah Brendan, being in a position of

  1. CHIEF BUSINESS OFFICER AND COO at Quince Therapeutics, Inc.,
    оver the last 12 months, has bought 38924 shares for $24,166, and sold 0 shares,
    over all time since 2023-08-08, has bought 110686 shares for $111,716, and sold 0 shares.

The largest purchase of all time was on 2023-08-08 and amounted to 71762 shares of Quince Therapeutics, Inc. for $87,550.

Biography of Hannah Brendan

No biography is available at this moment.

2024-08-21PurchaseQuince Therapeutics, Inc.
QNCX
CHIEF BUSINESS OFFICER AND COO
30,845
0.0698%
$0.63$19,337+17.19%
2024-08-20PurchaseQuince Therapeutics, Inc.
QNCX
CHIEF BUSINESS OFFICER AND COO
5,924
0.0136%
$0.60$3,579+21.72%
2024-08-19PurchaseQuince Therapeutics, Inc.
QNCX
CHIEF BUSINESS OFFICER AND COO
2,155
0.0047%
$0.58$1,250+20.49%
2023-08-08PurchaseQuince Therapeutics, Inc.
QNCX
Chief Business Officer
71,762
0.1975%
$1.22$87,550-13.11%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.